Nonalcoholic fatty liver disease among HIV-infected persons
- PMID: 19225402
- PMCID: PMC2782375
- DOI: 10.1097/QAI.0b013e318198a88a
Nonalcoholic fatty liver disease among HIV-infected persons
Abstract
Objective: To describe the prevalence and factors associated with nonalcoholic fatty liver disease (NAFLD) among HIV-infected persons not infected with hepatitis C virus (HCV).
Design: : A cross-sectional study among HIV-infected patients in a large HIV clinic.
Methods: NAFLD was defined as steatosis among patients without viral hepatitis (B or C) coinfection or excessive alcohol use. The prevalence of NAFLD was identified by ultrasound examination evaluated by 2 radiologists blinded to the clinic information; liver biopsies were performed on a subset of the study population. Factors associated with NAFLD were evaluated by proportional odds logistic regression models.
Results: Sixty-seven of 216 patients (31%) had NAFLD based on ultrasound evaluation. Among those with NAFLD, steatosis was graded as mild in 60%, moderate in 28%, and severe/marked in 12%. Factors associated with the degree of steatosis on ultrasound examination in the multivariate model included increased waist circumference [odds ratio (OR) 2.1 per 10 cm, P < 0.001], elevated triglyceride levels (OR 1.2 per 100 mg/dL, P = 0.03), and lower high-density lipoprotein levels (OR 0.7, per 10 mg/dL, P = 0.03). African Americans were less likely to have NAFLD compared with whites (14% vs. 35%), although this did not reach statistical significance (OR 0.4, P = 0.08). Similar associations were noted for the subset of patients diagnosed by liver biopsy. CD4 cell count, HIV viral load, duration of HIV infection, and antiretroviral medications were not independent risk factors associated with NAFLD after adjustment for dyslipidemia or waist circumference.
Conclusions: NAFLD was common among this cohort of HIV-infected HCV-seronegative patients. NAFLD was associated with a greater waist circumference, low high-density lipoprotein, and high triglyceride levels. Antiretroviral medications were not associated with NAFLD; prospective studies are needed to confirm this finding.
Conflict of interest statement
The opinions or ascertains contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Departments of the Army, Navy, or Air Force, or the Department of Defense. The authors have no commercial or other association that might pose a conflict of interest in this work.
Comment in
-
Nonalcoholic fatty liver disease in HIV-infected persons: epidemiology and the role of nucleoside reverse transcriptase inhibitors.J Acquir Immune Defic Syndr. 2010 Feb;53(2):278; author reply 278-81. doi: 10.1097/QAI.0b013e3181c990ed. J Acquir Immune Defic Syndr. 2010. PMID: 20104126 No abstract available.
Similar articles
-
Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.Clin Infect Dis. 2008 Jul 15;47(2):250-7. doi: 10.1086/589294. Clin Infect Dis. 2008. PMID: 18532884
-
Human immunodeficiency virus is the major determinant of steatosis and hepatitis C virus of insulin resistance in virus-associated fatty liver disease.Arch Med Res. 2011 Nov;42(8):690-7. doi: 10.1016/j.arcmed.2011.12.009. Epub 2012 Jan 4. Arch Med Res. 2011. PMID: 22227046
-
Traditional but not HIV-related factors are associated with nonalcoholic fatty liver disease in Asian patients with HIV-1 infection.PLoS One. 2014 Jan 31;9(1):e87596. doi: 10.1371/journal.pone.0087596. eCollection 2014. PLoS One. 2014. PMID: 24498148 Free PMC article. Clinical Trial.
-
Nonalcoholic fatty liver disease and HIV infection.Curr HIV/AIDS Rep. 2006 Sep;3(3):113-7. doi: 10.1007/BF02696654. Curr HIV/AIDS Rep. 2006. PMID: 16970837 Review.
-
Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection.AIDS. 2017 Jul 17;31(11):1621-1632. doi: 10.1097/QAD.0000000000001504. AIDS. 2017. PMID: 28398960 Review.
Cited by
-
Optimizing cardiometabolic risk in people living with human immunodeficiency virus: A deep dive into an important risk enhancer.Am J Prev Cardiol. 2024 Oct 28;20:100888. doi: 10.1016/j.ajpc.2024.100888. eCollection 2024 Dec. Am J Prev Cardiol. 2024. PMID: 39552706 Free PMC article. Review.
-
MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls.Aliment Pharmacol Ther. 2024 Nov;60(10):1351-1360. doi: 10.1111/apt.18236. Epub 2024 Sep 5. Aliment Pharmacol Ther. 2024. PMID: 39238213
-
Metabolic Dysfunction-Associated Steatotic Liver Disease in People Living with HIV-Limitations on Antiretroviral Therapy Selection.Life (Basel). 2024 Jun 10;14(6):742. doi: 10.3390/life14060742. Life (Basel). 2024. PMID: 38929725 Free PMC article. Review.
-
Discovery of Dolutegravir Derivative against Liver Cancer via Inducing Autophagy and DNA Damage.Molecules. 2024 Apr 13;29(8):1779. doi: 10.3390/molecules29081779. Molecules. 2024. PMID: 38675599 Free PMC article.
-
Regional variation in NAFLD prevalence and risk factors among people living with HIV in Europe: a meta-analysis.Front Public Health. 2024 Jan 4;11:1295165. doi: 10.3389/fpubh.2023.1295165. eCollection 2023. Front Public Health. 2024. PMID: 38259755 Free PMC article.
References
-
- Palella FJ, Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34. - PubMed
-
- Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492–497. - PubMed
-
- Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficieny virus: the D:A:D study. Arch Intern Med. 2006;166:1632–1641. - PubMed
-
- Pol S, Lebray P, Vallet-Pichard A. HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. Clin Infect Dis. 2004;38:S65–S72. - PubMed
-
- Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–438. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
